×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FOLD – amicus therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FOLD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/20
04:01 pm
fold
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Neutral
Report
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2/18
07:46 pm
fold
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]
Low
Report
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]
2/8
11:43 am
fold
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]
Low
Report
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]
2/8
04:28 am
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns [Yahoo! Finance]
2/3
08:00 am
fold
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Low
Report
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
2/1
06:25 am
fold
The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
Low
Report
The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
1/28
07:29 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/23
07:37 am
fold
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Low
Report
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
07:00 am
FOLD
amicus therapeutics, inc.
BEAT
Report
-1.2%
amicus therapeutics, inc.
7/31/2025
07:00 am
FOLD
amicus therapeutics, inc.
BEAT
Report
-6.4%
amicus therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/20
04:05 pm
fold
Form 10-K AMICUS THERAPEUTICS, For: Dec 31
Neutral
Report
Form 10-K AMICUS THERAPEUTICS, For: Dec 31
2/20
04:02 pm
fold
Form 8-K AMICUS THERAPEUTICS, For: Feb 20
Neutral
Report
Form 8-K AMICUS THERAPEUTICS, For: Feb 20
2/10
11:23 am
fold
Form SCHEDULE 13G/A AMICUS THERAPEUTICS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G/A AMICUS THERAPEUTICS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
2/9
03:18 pm
fold
Form SCHEDULE 13G/A AMICUS THERAPEUTICS, Filed by: WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
Low
Report
Form SCHEDULE 13G/A AMICUS THERAPEUTICS, Filed by: WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
2/2
08:30 am
fold
Form DEFM14A AMICUS THERAPEUTICS,
Low
Report
Form DEFM14A AMICUS THERAPEUTICS,
1/26
08:12 am
fold
Form DEFA14A AMICUS THERAPEUTICS,
Low
Report
Form DEFA14A AMICUS THERAPEUTICS,
1/26
08:11 am
fold
Form 8-K AMICUS THERAPEUTICS, For: Jan 26
Low
Report
Form 8-K AMICUS THERAPEUTICS, For: Jan 26
1/22
07:27 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 20 Filed by: Campbell Bradley L
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 20 Filed by: Campbell Bradley L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/2
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
8.5%
2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%
3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%
2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%
6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%
1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%
10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%
3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%
7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%
4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%
2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%
3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%
2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%
6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%
1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%
10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%
3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%
7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%
4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%
TOP News Decliners
10/3
Amicus snaps back on positive data from Pompe Disease study of AT-GAA [Seeking Alpha]
-10.0%
8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%
3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%
8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%
5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%
12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%
8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%
7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%
1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%
1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%
8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%
3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%
8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%
5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%
12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%
8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%
7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%
1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%
1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: